ArticleNanomedicine : nanotechnology, biology, and medicine2016
Targeted drug delivery to ischemic stroke via chlorotoxin-anchored, lexiscan-loaded nanoparticles.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Pathology-directed drug delivery strategies: How to overcome blood-brain barrier for the treatment of brain diseases.Acta pharmaceutica Sinica. B · 2026Review
- Inflammation Cascade-Directed Therapy by Biomimetic Polydopamine Nanosystem for Long-Term Management of Ischemic Stroke.Theranostics · 2026Article
- Article
- Nanomaterials and nanotechnology in otolaryngology: a narrative review.Nanomedicine (London, England) · 2025Review
- Photocuring CsA and bFGF-embedded hemostatic hydrogel promotes recovery from TBI by mitigating ferroptosis and neuroinflammation.iScience · 2025Article
- Emerging Targeted Delivery Strategies of Nanosystems for Ischemic Stroke Treatment.International journal of nanomedicine · 2025Review
- Nanotechnology approaches to drug delivery for the treatment of ischemic stroke.Bioactive materials · 2025Review
- Nanomedicine in Neuroprotection, Neuroregeneration, and Blood-Brain Barrier Modulation: A Narrative Review.Medicina (Kaunas, Lithuania) · 2024Review
- Autocatalytic, Brain Tumor-Targeting Delivery of Bardoxolone Methyl Self-Assembled Nanoparticles for Glioblastoma Treatment.Small science · 2024Article
- Polymeric nanocarriers delivery systems in ischemic stroke for targeted therapeutic strategies.Journal of nanobiotechnology · 2024Review
- How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.International journal of nanomedicine · 2024Review
- Nanotechnology-driven therapies for neurodegenerative diseases: a comprehensive review.Therapeutic delivery · 2024Review
- Discerning the Role of Blood Brain Barrier Dysfunction in Alzheimer's Disease.Aging and disease · 2022Article
- Brain-targeting, acid-responsive antioxidant nanoparticles for stroke treatment and drug delivery.Bioactive materials · 2022Article
- Brain Targeting, Antioxidant Polymeric Nanoparticles for Stroke Drug Delivery and Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2022Article
- Nanomaterials for Inner Ear Diseases: Challenges, Limitations and Opportunities.Materials (Basel, Switzerland) · 2022Review
- ZNF117 regulates glioblastoma stem cell differentiation towards oligodendroglial lineage.Nature communications · 2022Article
- Application and Utility of Liposomal Neuroprotective Agents and Biomimetic Nanoparticles for the Treatment of Ischemic Stroke.Pharmaceutics · 2022Review
- An Insight to Brain Targeting Utilizing Polymeric Nanoparticles: Effective Treatment Modalities for Neurological Disorders and Brain Tumor.Frontiers in bioengineering and biotechnology · 2022Review
- Targeting the Interaction of GABAFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ischemic stroke is a leading cause of disability and death worldwide. Current drug treatment for stroke remains inadequate due to the existence of the blood-brain barrier. We proposed an innovative nanotechnology-based autocatalytic targeting approach, in which the blood-brain barrier modulator lexiscan is encapsulated in nanoparticles to enhance blood-brain barrier permeability and autocatalytically augment the brain stroke-targeting delivery efficiency of chlorotoxin-anchored nanoparticles. The nanoparticles efficiently and specifically accumulated in the brain ischemic microenvironment and the targeting efficiency autocatalytically increased with subsequent administrations. When Nogo-66 receptor antagonist peptide NEP1-40, a potential therapeutic agent for ischemic stroke, was loaded, nanoparticles significantly reduced infarct volumes and enhanced survival. Our findings suggest that the autocatalytic targeting approach is a promising strategy for drug delivery to the ischemic microenvironment inside the brain. Nanoparticles developed in this study may serve as a new approach for the clinical management of stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.